PrEP-001, is an immunomodulator in Phase 2 for the prevention of influenza, influenza-like-illness and the common cold. These upper respiratory viral infections (URVIs) drive significant disease burden particularly for patients with underlying respiratory disorders (eg asthma and COPD) or weakened immune systems (eg the elderly). A nasally delivered powder containing a viral RNA surrogate, PrEP-001, triggers the innate immune system via the Rig-I, MDA5 and TLR3 receptors and is expected to provide a rapid, broad-spectrum prophylaxis against ~200 respiratory viruses. PrEP-001 is anticipated to be a first-to-market prophylactic nasal spray that creates a novel paradigm of prevention against these URVIs.
PrEP-001 has successfully completed two Phase 1b/2a double-blind, placebo controlled studies in more than 100 subjects that together demonstrate a pan-viral potential with safety and tolerability results similar to placebo. Two additional Phase 2a studies are ongoing and expected to read out in by 1Q2017.